Combined Hepatocellular-Cholangiocarcinoma: A Population-Level Analysis of an Uncommon Primary Liver Tumor
|
|
- Katrina Kelly
- 5 years ago
- Views:
Transcription
1 LIVER TRANSPLANTATION 20: , 2014 ORIGINAL ARTICLE Combined Hepatocellular-Cholangiocarcinoma: A Population-Level Analysis of an Uncommon Primary Liver Tumor Mattia Garancini, 1 Paolo Goffredo, 1 Fabio Pagni, 2 Fabrizio Romano, 1 Sanziana Roman, 3 Julie Ann Sosa, 3 and Vittorio Giardini 1 Departments of 1 General Surgery and 2 Pathology, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy; and 3 Section of Endocrine Surgery, Department of Surgery, Duke University, Durham, NC Combined hepatocellular-cholangiocarcinoma (chcc-cc) is a rare primary liver cancer. Our aims were to analyze the demographic, clinical, and pathological characteristics of chcc-cc at a population level and to investigate the effects of these features as well as different management strategies on the prognosis. The Surveillance, Epidemiology, and End Results (SEER) database was analyzed for Data analyses were performed with chi-square tests, analyses of variance, Kaplan- Meier curves, and Cox proportional hazards regression. Four hundred sixty-five patients with chcc-cc, 52,825 patients with hepatocellular carcinoma (HCC), and 7181 patients with cholangiocarcinoma (CC) were identified. chcc-cc was more common in patients who were white, male, and older than 65 years. Treatment was more frequently nonsurgical/interventional. Patients with chcc-cc, HCC, and CC had 5-year overall survival (OS) and disease-specific survival rates of 10.5%, 11.7%, and 5.7% (P < 0.001) and 17.8%, 21.0%, and 11.9% (P < 0.001), respectively. For chcc-cc patients, an increasing invasiveness of the therapeutic approach was significantly associated with prolonged survival (P < 0.001). In a multivariate model, black race, a distant SEER stage, and a tumor size of 5.0 to 10.0 cm were independently associated with lower survival for chcc-cc patients; a year of diagnosis after 1995 and surgical treatment with minor hepatectomy, major hepatectomy (MJH), or liver transplantation (LT) were independently associated with better survival for chcc-cc patients. Patients diagnosed with chcc-cc, HCC, and CC and treated with LT had 5-year OS rates of 41.1%, 67.0%, and 29.0%, respectively (P < 0.001). In conclusion, chcc-cc patients appear to have intermediate demographic, clinical, and survival characteristics in comparison with HCC and CC patients. chcc-cc patients undergoing LT showed inferior survival in comparison with HCC patients, and the role and indications for LT in chcc-cc have yet to be defined. At this time, MJH may be considered the best therapeutic approach for such patients. Liver Transpl 20: , VC 2014 AASLD. Received January 9, 2014; accepted April 21, Hepatocellular carcinoma (HCC), which originates from hepatocytes, and cholangiocarcinoma (CC), which arises from the intrahepatic bile duct epithelium, are the most common primary liver cancers. Combined hepatocellular-cholangiocarcinoma (chcc- CC) is a rare primary liver cancer displaying a mixture of histological characteristics of HCC and CC. It accounts for 0.4% to 14.2% of all primary hepatic tumors, with the incidence varying in different regions. 1-4 chcc-cc is considered an aggressive tumor associated with poor long-term survival. It is frequently misdiagnosed in the preoperative setting as either HCC or CC; usually, liver resection is considered the best therapeutic approach Previous studies of chcc-cc have mostly been single-center, retrospective analyses based on small Abbreviations: ABL, ablation; CC, cholangiocarcinoma; chcc-cc, combined hepatocellular-cholangiocarcinoma; DSS, diseasespecific survival; HCC, hepatocellular carcinoma; LT, liver transplantation; MJH, major hepatectomy; MNH, minor hepatectomy; NIT, no interventional treatment; NS, not significant; OS, overall survival; SEER, Surveillance; Epidemiology, and End Results. No funds, grants, or other financial support was received for this study. The authors have no conflicts of interest to declare. Address reprint requests to Mattia Garancini, M.D., Department of General Surgery, San Gerardo Hospital, University of Milano-Bicocca, Via Pergolesi 33, 20900, Monza (MB), Italy. Telephone: ; FAX: ; mattia_garancini@yahoo.it DOI /lt View this article online at wileyonlinelibrary.com. LIVER TRANSPLANTATION.DOI /lt. Published on behalf of the American Association for the Study of Liver Diseases VC 2014 American Association for the Study of Liver Diseases.
2 LIVER TRANSPLANTATION, Vol. 20, No. 8, 2014 GARANCINI ET AL. 953 series or literature reviews; no meta-analyses have been reported. Two population-level studies have been performed with data from a national database. One focused on epidemiological analysis, but it lacked information regarding therapeutic management 13 ; the second compared outcomes for patients with chcc- CC and HCC after liver transplantation (LT) or surgical resection but investigated only 3-year survival data for only 54 patients. 14 Therefore, to date, data on chcc-cc remain scarce. The current study was aimed at analyzing demographic, clinical, and pathological characteristics of chcc-cc versus HCC and CC at a population level, investigating prognostic factors of chcc-cc, and determining the impact of different therapeutic strategies on the survival of patients with this rare neoplasm. PATIENTS AND METHODS Data Sources and Study Patients The Surveillance, Epidemiology, and End Results (SEER) database was employed to identify patients diagnosed with chcc-cc, HCC, or CC between 1988 and This database uses the International Classification of Diseases for Oncology, 3rdedition, 16 for histology coding (chcc-cc, code 8180; HCC, codes ; and CC, codes ). Data were collected from 18 registries [San Francisco Oakland, Connecticut, metropolitan Detroit, Hawaii, Iowa, New Mexico, Utah (since 1973), Seattle Puget Sound (since 1974), metropolitan Atlanta (since 1975), Alaska, San Jose Monterey, Los Angeles, rural Georgia (since 1992), greater California (excluding San Francisco, Los Angeles, and San Jose), Kentucky, Louisiana, New Jersey, and greater Georgia (excluding Atlanta and rural Georgia, since 2000)], which represented nearly 28% of the US population. 17,18 Patients under the age of 18 years were excluded, and so were patients diagnosed between 1973 and 1987 because of the lack of data for surgical procedures before The demographic variables of interest were patient sex, age at diagnosis, race, marital status, and year of diagnosis. The age at diagnosis was classified as follows: 18 to 50, 51 to 65, 66 to 75, and 76 years. Race was recoded as white, black, or other; the marital status was categorized as married or single. The year of diagnosis was treated as a categorical variable divided into the following intervals: 1988 to 1995, 1996 to 2002, and 2003 to Clinical variables included overall survival (OS) and disease-specific survival (DSS) at 5 years and treatments. Interventional treatments were divided into 5 categories: no interventional treatment (NIT), ablation (ABL; including electrocautery, fulguration, cryosurgery, and alcohol injection), minor hepatectomy (MNH; including wedge resections and removal of 2 or fewer hepatic segments), major hepatectomy (MJH; removal of more than 2 segments), and LT. Pathological information included the tumor size, SEER stage, and lymph nodes examined. Tumors were divided into 4 groups according to size: 3.0, 3.1 to 5.0, 5.1 to 10.0, and >10.1 cm. Tumors > 25.0 cm were excluded because of the possibility of coding errors. According to the SEER system, a tumor is described as local if it is entirely limited to the organ, regional if it extends beyond the primary site to nearby lymph nodes or tissues, and distant if it metastasizes to distant organs or distant lymph nodes. 16 Lymph nodes were categorized as follows: none (no lymph nodes were examined), negative (all lymph nodes examined were negative), or positive. SEER data are publicly available, and all patient information is de-identified; therefore, the current study was deemed exempt from institutional review board approval. Statistical Analyses Demographic, clinical, and pathological data were analyzed with basic statistics; chi-square tests and analyses of variance were employed for the analyses of categorical and continuous variables, respectively. The Kaplan-Meier method was used to determine prognostic factors, and the log-rank test and the Breslow test were used to calculate statistical significance. Cox proportional hazards regression was used to identify variables independently associated with better survival. Hazard ratios and 95% confidence intervals were calculated for the strength of the association between each variable and survival. Data analyses were performed with SPSS 19.0 (SPSS, Inc., Chicago, IL); all tests were 2-sided, and statistical significance was set at P < RESULTS Demographic, Clinical, and Pathological Characteristics of Patients With chcc-cc A total of 52,825 patients with HCC, 7181 patients with CC, and 465 patients with chcc-cc were identified in the SEER database. chcc-cc was more common among patients who were white, male, and older than 65 years; the mean age at diagnosis was years. Treatment was more frequently noninterventional for all 3 types of tumors. Among chcc-cc patients, 65.2% did not receive any invasive treatment, 4.0% underwent tumor ABL, 7.6% underwent MNH, 10.0% underwent MJH, and 13.1% underwent LT. chcc-cc patients presented with a mean tumor size of cm. The SEER stage at diagnosis was local for 41.3% of the chcc-cc patients, regional for 29.1%, and distant for 29.6%. Among 54 patients with chcc-cc who underwent regional lymph node removal, 24.1% had lymph node metastases according to a pathological analysis. All results for patient characteristics are reported in Table 1.
3 954 GARANCINI ET AL. LIVER TRANSPLANTATION, August 2014 TABLE 1. Demographic, Clinical, and Pathological Characteristics of Patients Diagnosed With chcc-cc, HCC, and CC: SEER, Patient Characteristics chcc-cc (n 5 465) HCC (n 5 52,825) CC (n ) P Value Demographics Sex (%) <0.001* Male Female Age at diagnosis (years) <0.001 Age at diagnosis (%) years <0.001* years years Race (%) <0.001* White Black Other Marital status (%) 0.011* Married Single Year of diagnosis (%) <0.001* Clinical 5-year survival (%) OS <0.001 DSS <0.001 Treatment (%) k <0.001 NIT ABL MNH MJH Transplant Pathological Tumor size (cm) Tumor size (%) 3 cm <0.001* cm cm >10.1 cm SEER stage (%) <0.001* Local Regional Distant Regional lymph nodes examined (%) No <0.001* Yes <0.001* Negative Positive NOTE: Percentages have been rounded and may not add up to 100. *Chi-square test. The data are presented as means and standard deviations. Analysis of variance Log-rank test. k Data were available for 420 chcc-cc patients, 48,471 HCC patients, and 6350 CC patients. The OS rates at 5 years for chcc-cc, HCC, and CC patients were 10.5%, 11.7%, and 5.7%, respectively (P < 0.001); the 5-year DSS rates were 17.8%, 21.0%, and 11.9%, respectively (P < 0.001). DSS curves for chcc-cc, HCC, and CC are shown in Fig. 1. Analysis of Risk Factors for Compromised Survival in chcc-cc Patients In the univariate analysis, black race, regional and distant SEER stages, and a tumor size > 3 cm were
4 LIVER TRANSPLANTATION, Vol. 20, No. 8, 2014 GARANCINI ET AL. 955 associated with lower DSS; a year of diagnosis after 1995, interventional treatments (ABL, MJH, MNH, and LT), and an absence of regional lymph node metastases Figure 1. DSS curves for chcc-cc, HCC, and CC. were positive prognostic factors (Table 2). In the univariate analysis, LT was associated with better 5-year OS in a direct comparison with liver resection (major and minor; P ; data not shown in the tables). In the multivariate analysis, black race, distant SEER stage, and a tumor size of 5.1 to 10.0 cm remained independently associated with compromised 5-year DSS; patients diagnosed after 1995 and patients who were treated with surgery that included MNH, MJH, or LT had better outcomes (Table 3). Because black race was newly found to be a negative prognostic factor, differences between white and black patients were analyzed in terms of disease presentation and type of treatment. Black patients did not differ fromwhitepatientsintermsofage(p ), tumor size (P ), or SEER stage (P ) at presentation or in terms of the type of treatment (P ). Patients diagnosed with chcc-cc and treated with LT, MJH, MNH, ABL, and NIT had 5-year OS rates of 41.1%, 28.1%, 27.1%, 0%, and 0%, respectively, and DSS rates of 52.8%, 46.5%, 31.9%, 0%, and 3.2%, respectively (P < for both; Fig. 2). Surgical therapy with LT or liver resection (major or minor) granted longer DSS than more conservative treatments. In order to investigate whether the survival results of these subgroups of patients could have been due to selection criteria, patients who underwent different treatment strategies were stratified by tumor size and TABLE 2. Univariate Analysis of Disease-Specific Mortality Characteristics Hazard Ratio* 95% Confidence Interval P Value Race White 1 Reference Black Other NS Year of diagnosis Reference <0.001 SEER stage Local 1 Reference Regional <0.001 Distant <0.001 Treatment NIT 1 Reference ABL MNH <0.001 MJH <0.001 Transplant <0.001 Tumor size cm 1 Reference cm cm < cm <0.001 Lymph nodes examined Negative 1 Reference Positive <0.001 No *A hazard ratio less than 1 indicates better survival.
5 956 GARANCINI ET AL. LIVER TRANSPLANTATION, August 2014 TABLE 3. Cox Multivariate Regression Analysis of Factors Independently Associated With Disease-Specific Death Risk Factor Hazard Ratio* 95% Confidence Interval P Value Black race Year of diagnosis, Year of diagnosis, Distant SEER stage <0.001 Tumor size, cm MNH <0.001 MJH <0.001 Transplant <0.001 NOTE: The total number was 271, and the number of events was 151. The reference groups are white race; year of diagnosis, ; localized SEER stage; tumor size, cm; and no surgery. *A hazard ratio less than 1 indicates better survival. Figure 2. DSS curves (univariate analysis) for chcc-cc patients stratified by the type of treatment. SEER stage. Patients treated with MJH, MNH, and LT did not differ in SEER stage (P ), but LT was mostly performed in patients with small tumors (3 cm), whereas liver resection (particularly MJH) was mostly performed in patients with larger tumors (>3 or even >5 cm, P < 0.001; Fig. 3). Finally, the 3 groups of tumors were compared in terms of survival after LT. Patients diagnosed with chcc-cc, HCC, and CC had 5-year OS rates of 41.1%, 67.0%, and 29.0%, respectively (P < 0.001), and 5-year DSS rates of 52.8%, 80.2%, and 46.6%, respectively (P < 0.001). DISCUSSION Figure 3. Subgroups of patients with chcc-cc receiving different treatments are detailed in terms of SEER stages and tumor sizes. To the best of our knowledge, the current study includes the largest published cohort of patients diagnosed with chcc-cc. This malignancy showed a clinical course intermediate between the courses of HCC and CC. The 5-year DSS rate was 17.8%. Surgical treatment with liver resection or transplantation was associated with prolonged DSS. The incidence of chcc-cc in published series of primary liver-based cancers ranges from 0.4% to 14.2%. 2-4 In our cohort, chcc-cc was observed in 465 of 60,471 patients (0.77%) with primary liver
6 LIVER TRANSPLANTATION, Vol. 20, No. 8, 2014 GARANCINI ET AL. 957 cancer. The true incidence was likely higher because patients who did not undergo interventional procedures may have been clinically misdiagnosed with HCC or CC. Patients diagnosed with chcc-cc had intermediate features of HCC and CC. In the literature, chcc-cc has been reported to be similar to HCC in terms of patient demographic and clinical characteristics: a male-to-female ratio of 1 has been described as well male prevalence, an average age at presentation between 50 and 60 years, and an elevation of serum alpha-fetoprotein. 6,9,10,13 Our analyses showed that men were more commonly affected than women (66%), and patients were older than 60 years at the time of diagnosis (mean age at diagnosis years). Data regarding hepatitis virus infections, background liver status, and biomarkers such as alphafetoprotein were not captured in the SEER database before 2004 and, consequently, were not included in the present analysis; they have been analyzed in the literature with contrasting results. 2,6,9,10,19,20 Our findings with respect to pathological characteristics, including the mean tumor size at diagnosis and lymph node metastases, were consistent with previous surgical series. 10 Nevertheless, our data probably led to an underestimation because of the low number of patients receiving surgical treatment. In a Japanese study based on 12,887 autopsies performed in patients with primary liver cancers, 76% of 49 patients with chcc-cc had lymph node metastases. 21 After adjustments for several factors, including tumor size and SEER stage, we did not observe lower survival outcomes for patients with nodal metastases, and this confirmed the findings of previous investigators. 2,8,10,22 A diagnosis in recent years appeared to be associated with a better prognosis; in fact, long-term survival rates for many types of cancers have substantially improved over the past decades because of advances in early detection and treatment. 23 Black race was newly found to be a negative prognostic factor. Several studies published on chcc-cc have focused on Asian populations because of the higher incidence of hepatic neoplasms in those countries; Asians were poorly represented in our series, so we could not analyze this subset of patients. In the present study, all 3 types of analyzed neoplasms had a 5-year DSS rate lower than 21%. These results could appear disappointing, especially because 5-year survival rates up to 60% to 70% can be achieved for well-selected HCC patients. 24,25 Nevertheless, these results include the fact that 65% to 84% of the patients included in this study did not receive any kind of interventional treatment. This might have been due to a diagnosis performed in a setting of advanced disease (regional or distant SEER stage, large tumors, and multiple nodules). In the literature, the long-term survival of patients with chcc-cc is controversial: Yin et al. 10 reported a 5-year OS rate of 36.4% for resected chcc-cc patients; Kim et al. 6 reported a 3-year OS rate of 15.3%; and the 5-year OS rates for resected patients were 24% and 7.9% according to Jarnagin et al. 2 and Zuo et al. 9 Tang et al. 26 analyzed 13 patients who had undergone resection and reported a 5-year OS rate- > 50% for select patients with early-stage chcc-cc. 26 Our results clearly show how the survival of chcc- CC patients is strictly related to the type of treatment received: patients not undergoing any invasive therapy or treated with local ABL had a much poorer prognosis than those undergoing LT and liver resection (Fig. 2). HCC is a universally accepted indication for LT with excellent 5-year OS (exceeding 70% in select patients). 27,28 CC is not currently considered a standard indication for LT. Previous studies of LT for intrahepatic CC reported discouraging 5-year survival rates of 20% to 30% or less, mainly because of high recurrence rates (>50%) Nevertheless, in more recent years, some studies restricted to patients with CC located at the hepatic hilum who were treated with neoadjuvant chemoradiation therapies showed remarkable survival benefits; the most important report in this sense is the experience of the Mayo Clinic, which achieved a 5-year survival rate of 82% for patients with CC located at the hepatic hilum. 32 Therefore, some authors now believe that additional research should be aggressively pursued, and this potentially effective treatment should be balanced with the severe organ shortage. 33 Similarly to CC, chcc-cc is not yet considered an indication for LT, and in the present study (as in the literature), most of the patients who underwent LT for chcc-cc probably had a misdiagnosis of HCC. In the literature, studies including patients with chcc-cc treated with LT are seldom reported, and this makes an evaluation of possible indications quite challenging. Maganty et al. 34 described long-term survival (>5 years) for 1 patient among 3 carriers of chcc-cc who had undergone LT. Panjala et al. 35 reported a 5-year cumulative survival rate of 16% for a cohort of 12 patients with chcc-cc treated with LT. Sapisochin et al. 36 reported a 5-year recurrence-free survival rate of 32% for a study group including chcc-cc and CC patients treated with LT for misdiagnosed HCC; within this study group of patients, they found that the patients with chcc-cc had a worse prognosis, a higher rate of tumor recurrence, and a shorter period of disease-free survival in comparison with the patients with CC. Employing the SEER database ( ), Groeschl et al. 14 compared the surgical management of chcc-cc and HCC. Among patients with chcc- CC, the 3-year OS rates after LT and liver resection were similar (48% versus 46%, P ); moreover, they reported significantly worst OS for chcc-cc patients versus HCC patients after LT. Our univariate analysis of chcc-cc patients showed that individuals who underwent LT had better 5-year OS than those who were treated with MJH or MNH (P ). These results were not confirmed in the multivariate analysis, in which LT, MJH, and MNH had similar hazard ratios (0.28, 0.25, and 0.29, respectively).
7 958 GARANCINI ET AL. LIVER TRANSPLANTATION, August 2014 In the current study, patients treated with LT achieved interesting 5-year OS and DSS rates of 41.1% and 52.8%, respectively, which can be considered intermediate results between those obtained for HCC and intrahepatic CC in the present study and in the literature. 24,29-31 The results of the multivariate analysis devalued this supposed survival benefit of LT for chcc-cc patients and showed that patient selection probably played a relevant role. On the other hand, it is remarkable that among 55 patients with chcc-cc who underwent LT, 16 were SEER-staged as regional, and 4 had a tumor size > 5 cm; overall, 17 of the 55 patients (30.9%) had at least 1 of these 2 well-known negative prognostic factors for LT in the setting of HCC. Therefore, better patient selection may improve these outcomes. Nonetheless, HCC patients had similar outcomes before the definition of the Milan criteria in ,37-39 Currently, organ allocation in the United States of America does not give priority to patients with chcc-cc; most of the patients who underwent LT for chcc-cc in this study probably had a misdiagnosis of HCC and underwent transplantation within the Milan criteria, which were designed for HCC and not for chcc-cc. This aspect should be considered when the potential role of LT for chcc-cc is analyzed. More clinical data on chcc-cc are clearly needed, and the organ shortage represents the main limitation in this sense. Previous studies seldom detailed the type of liver resection performed; in some cases, a distinction between radical resection and palliative resection was reported. 9 In the present study, we subdivided resective surgical treatments into MJH and MNH. Interestingly, both were independently associated with better survival, but patients undergoing MJH had better OS and DSS. Compared to patients undergoing LT or MNH, patients undergoing MJH had similar SEER stages (P ) but larger tumors (P < 0.001; Fig. 3). Because MJH was associated with higher 5-year OS and DSS rates than MNH for patients with similar (or worst) demographic and clinical characteristics and because the role and indications of LT for chcc-cc patients have yet to be defined, our results suggest that at this time, MJH should be considered the best surgical approach. Clearly, the background status of the liver (the presence of cirrhosis or chronic hepatitis with impaired liver function) should be taken into account, and the benefits of surgery should be weighed against the morbidity and mortality associated with major liver resections. 40 The role of nonsurgical therapies such as local ablative therapy and transarterial chemoembolization in chcc-cc requires further evaluation. Some studies have reported that they could play a role in the presence of unresectable or recurrent disease. 2,10 This study has some limitations. This is a retrospective study, and consequently, some bias may have affected the analysis. Moreover, the SEER database lacks information before 2004 regarding patient status with respect to the presence or absence of viral hepatitis or cirrhosis in the background liver as well as alpha-fetoprotein and carbohydrate antigen 19-9 levels and the use of chemotherapy. Nevertheless, chemotherapy for HCC, CC, and chcc-cc has shown little impact on patient survival. Moreover, SEER lacks a central review by an expert pathologist. However, the SEER database has been well validated for cancer research by several studies In conclusion, chcc-cc appears to show intermediate demographic, clinical, and survival characteristics of HCC and CC. As for the management of this rare neoplasm, an aggressive approach showed a survival benefit and should be recommended. LT showed interesting results in terms of survival, but it does not offer a benefit in comparison with major or minor liver resection; consequently, its role and indications for chcc-cc patients have yet to be defined. At this time, MJH may be considered the best therapeutic approach for these patients. Further studies should analyze the real incidence of chcc-cc and identify optimal methods for making a preoperative diagnosis. Thus, a better definition of the size of this problem could open the field to a more rational approach to chcc-cc management. REFERENCES 1. Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, Joh JW. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today 2006;36: Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 2002;94: Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol 1949;25: Lee CC, Wu CY, Chen JT, Chen GH. Comparing combined hepatocellular-cholangiocarcinoma and cholangiocarcinoma: a clinicopathological study. Hepatogastroenterology 2002;49: Chok KS, Ng KK, Cheung TT, Yuen WK, Poon RT, Lo CM, Fan ST. An update on long-term outcome of curative hepatic resection for hepatocholangiocarcinoma. World J Surg 2009;33: Kim W, Lee JH, Kim YJ, Yoon JH, Suh KS, Lee KU, et al. Analysis of prognostic factors after curative resection for combined hepatocellular and cholangiocarcinoma [in Korean]. Korean J Gastroenterol 2007;49: Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol 2009;16: Kassahun WT, Hauss J. Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract 2008; 62: Zuo HQ, Yan LN, Zeng Y, Yang JY, Luo HZ, Liu JW, Zhou LX. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2007;6: Yin X, Zhang BH, Qiu SJ, Ren ZG, Zhou J, Chen XH, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol 2012;19: Lee CH, Hsieh SY, Chang CJ, Lin YJ. Comparison of clinical characteristics of combined hepatocellular-
8 LIVER TRANSPLANTATION, Vol. 20, No. 8, 2014 GARANCINI ET AL. 959 cholangiocarcinoma and other primary liver cancers. J Gastroenterol Hepatol 2013;28: Lee JH, Chung GE, Yu SJ, Hwang SY, Kim JS, Kim HY, et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol 2011;45: Wachtel MS, Zhang Y, Xu T, Chiriva-Internati M, Frezza EE. Combined hepatocellular cholangiocarcinomas; analysis of a large database. Clin Med Pathol 2008;1: Groeschl RT, Turaga KK, Gamblin TC. Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma. J Surg Oncol 2013; 107: National Cancer Institute. SEER: Surveillance, Epidemiology, and End Results Program. Accessed February Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; International-Classification-Diseases-Oncology-ICD-O/dp/ /ref=sr_1_1?s=books&ie=UTF8&qid= &sr=1-1&keywords=fritz+a+international+classification+of+ Diseases+for+Oncology. 17. National Cancer Institute. About the SEER registries. Accessed February National Cancer Institute. Glossary of statistical terms. Accessed February Cai X, Zhai J, Kaplan DE, Zhang Y, Zhou L, Chen X, et al. Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular-cholangiocarcinoma. Hepatology 2012;56: Okabayashi T, Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Takayama T, Makuuchi M. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001;92: Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 1990;211: Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada K, et al. Combined hepatocellular and cholangiocarcinoma: clinicopathologic study of 26 resected cases. Jpn J Clin Oncol 2003;33: Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 2002;360: Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011;17(suppl 2):S44-S Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362: Tang D, Nagano H, Nakamura M, Wada H, Marubashi S, Miyamoto A, et al. Clinical and pathological features of Allen s type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg 2006;10: Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;11: Jonas S, Bechstein WO, Steinm uller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001;33: Goldstein RM, Stone M, Tillery GW, Senzer N, Levy M, Husberg BS, et al. Is liver transplantation indicated for cholangiocarcinoma? Am J Surg 1993;166: Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000;69: Brandsaeter B, Isoniemi H, Broome U, Olausson M, B ackman L, Hansen B, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004;40: Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242: Schwartz JJ, Hutson WR, Gayowski TJ, Sorensen JB. Liver transplantation for cholangiocarcinoma. Transplantation 2009;88: Maganty K, Levi D, Moon J, Bejarano PA, Arosemena L, Tzakis A, Martin P. Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: outcome after liver transplantation. Dig Dis Sci 2010;55: Panjala C, Senecal DL, Bridges MD, Kim GP, Nakhleh RE, Nguyen JH, Harnois DM. The diagnostic conundrum and liver transplantation outcome for combined hepatocellular-cholangiocarcinoma. Am J Transplant 2010;10: Sapisochin G, Fidelman N, Roberts JP, Yao FY. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl 2011;17: Olthoff KM, Millis JM, Rosove MH, Goldstein LI, Ramming KP, Busuttil RW. Is liver transplantation justified for the treatment of hepatic malignancies? Arch Surg 1990;125: Haug CE, Jenkins RL, Rohrer RJ, Auchincloss H, Delmonico FL, Freeman RB, et al. Liver transplantation for primary hepatic cancer. Transplantation 1992;53: Moreno Gonzalez E, Gomez R, Garcıa I, Gonzalez-Pinto I, Loinaz C, Iba~nez J, et al. Liver transplantation in malignant primary hepatic neoplasms. Am J Surg 1992;163: Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, et al. Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg 2002;236: National Cancer Institute. SEER quality improvement. Accessed February Harlan LC, Hankey BF. The Surveillance, Epidemiology, and End-Results Program database as a resource for conducting descriptive epidemiologic and clinical studies. J Clin Oncol 2003;21: Yu JB, Gross CP, Wilson LD, Smith BD. NCI SEER public-use data: applications and limitations in oncology research. Oncology (Williston Park) 2009;23:
Natural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry
2015;112:872 876 Natural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry PETER L. JERNIGAN, MD, KOFFI WIMA, MS, DENNIS J. HANSEMAN, PhD, RICHARD
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationMixed Hepatocellular Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma in Patients Undergoing Transplantation for Hepatocellular Carcinoma
LIVER TRANSPLANTATION 17:934-942, 2011 ORIGINAL ARTICLE Mixed Hepatocellular Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma in Patients Undergoing Transplantation for Hepatocellular Carcinoma Gonzalo
More informationRESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment
DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,
More informationDuring the past 2 decades, an increase in the ageadjusted
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:104 110 Racial Differences in Survival of Hepatocellular Carcinoma in the United States: A Population-Based Study JESSICA A. DAVILA* and HASHEM B. EL SERAG*,
More informationHPB ORIGINAL ARTICLE. Abstract. Correspondence. Introduction
http://dx.doi.org/10.1016/j.hpb.2015.10.001 HPB ORIGINAL ARTICLE Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of
More informationLiving Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?
Original Article Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? R. F. Saidi 1 *, Y. Li 2, S. A. Shah 2, N. Jabbour 2 1 Division of Organ Transplantation, Department
More informationTHE SURVIVORSHIP EXPERIENCE IN PANCREATIC CANCER
THE SURVIVORSHIP EXPERIENCE IN PANCREATIC CANCER Casey A. Boyd, Jaime Benarroch, Kristin M. Sheffield, Yimei Han, Catherine D. Cooksley, Taylor S. Riall Department of Surgery The University of Texas Medical
More informationIs Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer?
Is Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer? Lee H, Park JY, Youn S, Kwon W, Heo JS, Choi SH, Choi DW Department of Surgery, Samsung Medical Center Sungkyunkwan
More informationTREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD
TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE
More informationCurrent status of hepatic surgery in Korea
Korean J Hepatol. 2009 Dec; 15(Suppl 6):S60 - S64. DOI: 10.3350/kjhep.2009.15.S6.S60 Current status of hepatic surgery in Korea Kyung Sik Kim Department of Surgery, Severance Hospital, Yonsei University
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationFibrolamellar carcinoma (FLC) is a rare primary hepatic
Is Fibrolamellar Different From Hepatocellular? A US Population-Based Study Hashem B. El-Serag 1,2 and Jessica A. Davila 1 There have been no population-based studies of the epidemiology and prognosis
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationExtending Indication: Role of Living Donor Liver Transplantation for Hepatocellular Carcinoma
LIVER TRANSPLANTATION 13:S48-S54, 27 SUPPLEMENT Extending Indication: Role of Living Donor Liver Transplantation for Hepatocellular Carcinoma Satoru Todo, 1 Hiroyuki Furukawa, 2 Mitsuhiro Tada, 3 and the
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationLiving donor liver transplantation for patients with hepatocellular carcinoma in Japan
Sugawara et al. Hepatoma Res 2018;4:33 DOI: 10.20517/2394-5079.2018.69 Hepatoma Research Review Open Access Living donor liver transplantation for patients with hepatocellular carcinoma in Japan Yasuhiko
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More information21/02/2014. Disclosures. HCC: predicting recurrence. Outline. Liver transplant: Beyond Milan?
Disclosures HCC: predicting recurrence Peter Ghali, MD, FRCPC, MSc (epid) None relevant to this talk other than off-label use of sirolimus Toronto, February 2014 Outline Recurrence after what? Locoregional
More informationHepatocellular carcinoma (HCC) is the most
Original Article / Biliary Hepatobiliary & Pancreatic Diseases International Prognosis of hepatocellular carcinoma with bile duct tumor thrombus after R0 resection: a matched study Ding-Ding Wang, Li-Qun
More informationConditional Colon Cancer Survival in the United States
Research Article imedpub Journals http://www.imedpub.com Colorectal Cancer: Open Access DOI: 10.21767/2471-9943.100020 Abstract Conditional Colon Cancer Survival in the United States Purpose: As long-term
More informationChapter 13 Cancer of the Female Breast
Lynn A. Gloeckler Ries and Milton P. Eisner INTRODUCTION This study presents survival analyses for female breast cancer based on 302,763 adult cases from the Surveillance, Epidemiology, and End Results
More informationIntrahepatic cholangiocarcinoma: the AJCC/UICC 8 th edition updates
Review Article Page 1 of 5 Intrahepatic cholangiocarcinoma: the AJCC/UICC 8 th edition updates Andrew J. Lee, Yun Shin Chun Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center,
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationThe impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis
Received: 1 May 2017 Accepted: 23 May 2017 DOI: 10.1002/jso.24727 RESEARCH ARTICLE The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis
More informationThe projection of short- and long-term survival for. Conditional Survival Among Patients With Carcinoma of the Lung*
Conditional Survival Among Patients With Carcinoma of the Lung* Ray M. Merrill, PhD, MPH; Donald Earl Henson, MD; and Michael Barnes, PhD Objective: One- and 5-year probabilities of survival or death change
More informationEFFICACY OF NECK DISSECTION FOR LOCOREGIONAL FAILURES VERSUS ISOLATED NODAL FAILURES IN NASOPHARYNGEAL CARCINOMA
ORIGINAL ARTICLE EFFICACY OF NECK DISSECTION FOR LOCOREGIONAL FAILURES VERSUS ISOLATED NODAL FAILURES IN NASOPHARYNGEAL CARCINOMA Raymond King Yin Tsang, FRCSEd, Joseph Chun Kit Chung, MRCSEd, Yiu Wing
More informationProximal Bile Duct Cancer: Contemporary Management. William R. Jarnagin, MD, FACS
Proximal Bile Duct Cancer: Contemporary Management William R. Jarnagin, MD, FACS Biliary Tract Adenocarcinoma Spectrum of disease Intrahepatic (IHC) Hilar EH Gallbladder GB CBD Distal D PD Biliary Tract
More informationLog odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection
Original Article Log odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection Mingjian Yang 1,2, Hongdian Zhang 1,2, Zhao Ma 1,2, Lei Gong 1,2, Chuangui Chen
More informationThe Effect of Changing Hysterectomy Prevalence on Trends in Endometrial Cancer, SEER
The Effect of Changing Hysterectomy Prevalence on Trends in Endometrial Cancer, SEER 1992-2008 Annie Noone noonea@mail.nih.gov Missy Jamison, Lynn Ries, Brenda Edwards NAACCR 2012 Portland, OR Outline
More informationHow to apply HCC prediction models to practice?
How to apply HCC prediction models to practice? Department of Internal Medicine, Keimyung University School of Medicine Woo Jin Chung HCC prediction models 독특하게간세포암환자들의생존은암의진행상태뿐아니라기저간기능의중증정도에영향을받는특성이있다.
More informationClinical analysis of 29 cases of nasal mucosal malignant melanoma
1166 Clinical analysis of 29 cases of nasal mucosal malignant melanoma HUANXIN YU and GANG LIU Department of Otorhinolaryngology Head and Neck Surgery, Tianjin Huanhu Hospital, Tianjin 300060, P.R. China
More informationLiver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals
Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer
More informationMacroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC/UICC TNM staging system
/, 2017, Vol. 8, (No. 60), pp: 101165-101174 Macroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC/UICC TNM staging system Ze-Wu Meng 1,2,*, Wei Pan 1,2, Hai-Jie Hong 1,2,
More informationSurgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London
Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationThe incidence of salivary carcinoma ex pleomorphic adenoma: A SEER database review and review of the literature
ORIGINAL ARTICLE The incidence of salivary carcinoma ex pleomorphic adenoma: A SEER database review and review of the literature Carl Rebhun, Richard O. Wein 1. School of Medicine, Tufts University, United
More informationInverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma
DOI:10.1111/j.1477-2574.2012.00507.x HPB ORIGINAL ARTICLE Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma Umut Sarpel 1, Diego Ayo 2, Iryna Lobach 3, Ruliang Xu 4
More informationSelection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation
Title Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation Author(s) Chan, SC; Fan, ST Citation Hepatobiliary Surgery and Nutrition, 2013, v. 2 n. 2, p.
More informationChibueze Onyemkpa 1, Alan Davis 1, Michael McLeod 1, Tolutope Oyasiji 1,2. Original Article
Original Article Typical carcinoids, goblet cell carcinoids, mixed adenoneuroendocrine carcinomas, neuroendocrine carcinomas and adenocarcinomas of the appendix: a comparative analysis of survival profile
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationLiving donor liver transplantation for hepatocellular carcinoma in Seoul National University
Original Article on Liver Transplantation for Hepatocellular Carcinoma Living donor liver transplantation for hepatocellular carcinoma in Seoul National University Suk Kyun Hong, Kwang-Woong Lee, Hyo-Sin
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationNIH Public Access Author Manuscript J Surg Res. Author manuscript; available in PMC 2011 May 18.
NIH Public Access Author Manuscript Published in final edited form as: J Surg Res. 2011 April ; 166(2): 189 193. doi:10.1016/j.jss.2010.04.036. Hepatocellular Carcinoma Survival in Uninsured and Underinsured
More informationLiving donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital
Original Article on Liver Transplantation for Hepatocellular Carcinoma Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital Junichi Togashi, Nobuhisa Akamastu,
More informationCurrent status of liver diseases in Korea: Hepatocellular carcinoma
Korean J Hepatol. 2009 Dec; 15(Suppl 6):S50 - S59. DOI: 10.3350/kjhep.2009.15.S6.S50 Current status of liver diseases in Korea: Hepatocellular carcinoma Il Han Song 1,3, Kyung Sik Kim 2,3 1 Division of
More informationRESEARCH ARTICLE. Di-Ya Wang 1&, Lei Liu 2&, Xing-Shun Qi 3& *, Chun-Ping Su 4, Xue Chen 3, Xu Liu 3, Jiang Chen 3, Hong-Yu Li 3, Xiao-Zhong Guo 3 *
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.13.5573 Re-Resection versus TACE for Recurrent HCC - a Meta-Analysis RESEARCH ARTICLE Hepatic Re-resection Versus Transarterial Chemoembolization for the Treatment
More informationAnalysis of prognostic factors of more/equal to10 years of survival for liver cancer patients after liver transplantation
Journal of Cancer Research and Clinical Oncology (2018) 144:2465 2474 https://doi.org/10.1007/s00432-018-2756-8 ORIGINAL ARTICLE CLINICAL ONCOLOGY Analysis of prognostic factors of more/equal to10 years
More informationPrognosis of Hepatocellular Carcinoma after Liver Transplantation: Comparative Analysis with Partial Hepatectomy
Journal of Pathology and Translational Medicine 2017; 51: 79-86 ORIGINAL ARTICLE Prognosis of Hepatocellular Carcinoma after Liver Transplantation: Comparative Analysis with Partial Hepatectomy Kyuho Lee
More informationChronic infections with hepatitis B and hepatitis C
Original Article / Liver The impact of family history of hepatocellular carcinoma on its patients' survival Wing Chiu Dai, Sheung Tat Fan, Tan To Cheung, Kenneth SH Chok, Albert CY Chan, Simon HY Tsang,
More informationPeri-Transplant Change in AFP Level: A Useful Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation
ORIGINAL ARTICLE Cell Therapy & Organ Transplantation http://dx.doi.org/1.3346/jkms.16.31.7.149 J Korean Med Sci 16; 31: 149-154 Peri-Transplant Change in AFP Level: A Useful Predictor of Hepatocellular
More informationPoor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas
10 The Open Otorhinolaryngology Journal, 2011, 5, 10-14 Open Access Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas Kevin C. Huoh and Steven J. Wang * Head and Neck Surgery and Oncology,
More informationEthnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer. Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD,
Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD, MD, Paul Hebert, PhD, Michael C. Iannuzzi, MD, and
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationPrognostic factors in curatively resected pathological stage I lung adenocarcinoma
Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,
More informationSurgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database
Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Hadi Khan, MD 1, Adam J. Olszewski, MD 2 and Ponnandai S. Somasundar, MD 1 1 Department
More informationHysterectomy-Corrected Rates of Endometrial Cancer among Women of Reproductive Age
Hysterectomy-Corrected Rates of Endometrial Cancer among Women of Reproductive Age Annie Noone noonea@mail.nih.gov NAACCR 2017 Albuquerque, NM Motivation Cancer incidence rates are typically calculated
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More informationFactors predictive of myoinvasion in cases of Complex Atypical Hyperplasia diagnosed on endometrial biopsy or curettage
Factors predictive of myoinvasion in cases of Complex Atypical Hyperplasia diagnosed on endometrial biopsy or curettage Jessica Johns, MD Jeffrey Killeen, MD Robert Kim, MD Hyeong Jun Ahn, PhD None Disclosures
More informationLaparoscopic Liver Resection for Hepatocellular Carcinoma
Original Article Laparoscopic Liver Resection for Hepatocellular Carcinoma Carmen D. Chung, Lydia L. Lau, Kwan Lung Ko, Andrew C. Wong, Shezam Wong, Albert C. Chan, Ronnie T. Poon, Chung Mau Lo and Sheung
More informationAnalysis of the outcome of young age tongue squamous cell carcinoma
Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of
More informationBile duct invasion can be an independent prognostic factor in early stage hepatocellular carcinoma
Korean J Hepatobiliary Pancreat Surg 2015;19:167-172 http://dx.doi.org/10.14701/kjhbps.2015.19.4.167 Original Article Bile duct invasion can be an independent prognostic factor in early stage hepatocellular
More informationHepatocellular Carcinoma: Epidemiology and Screening
Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationResearch Article Clinical Features and Outcomes Differ between Skeletal and Extraskeletal Osteosarcoma
Sarcoma, Article ID 902620, 8 pages http://dx.doi.org/10.1155/2014/902620 Research Article Clinical Features and Outcomes Differ between and Osteosarcoma Sheila Thampi, 1 Katherine K. Matthay, 1 W. John
More informationCombined Hepatocellular and Cholangiocarcinoma (Biphenotypic) Tumors: Imaging Features and Diagnostic Accuracy of Contrast- Enhanced CT and MRI
Gastrointestinal Imaging Original Research Fowler et al. Imaging Biphenotypic Tumors Gastrointestinal Imaging Original Research Kathryn J. Fowler 1 Arman Sheybani 2 Rex A. Parker, III 3 Sean Doherty 1
More informationHepatocellular Carcinoma in Qatar
Hepatocellular Carcinoma in Qatar K. I. Rasul 1, S. H. Al-Azawi 1, P. Chandra 2 1 NCCCR, 2 Medical Research Centre, Hamad Medical Corporation, Doha, Qatar Abstract Objective The main aim of this study
More informationManagement of hepatocellular carcinoma should consider both tumor factors and background liver factors
Hepatocellular Carcinoma Column: Editorial Management of hepatocellular carcinoma should consider both tumor factors and background liver factors Shuji Nomoto, Mitsuhiro Hishida, Yoshikuni Inokawa, Hiroyuki
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationInitial surgery for differentiated thyroid cancer: What is the appropriate extent and attendant risks and benefits?
Initial surgery for differentiated thyroid cancer: What is the appropriate extent and attendant risks and benefits? Julie Ann Sosa, MD MA FACS Professor of Surgery and Medicine Chief, Section of Endocrine
More informationHepatocellular carcinoma (HCC) is the thirdmost. Emerging Trends in Hepatocellular Carcinoma Incidence and Mortality
Emerging Trends in Hepatocellular Carcinoma Incidence and Mortality Basile Njei, 1,2 Yaron Rotman, 3 Ivo Ditah, 4 and Joseph K. Lim 1 The rise in incidence of hepatocellular carcinoma (HCC) in the United
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationTakahito Nakagawa, MD, Toshiya Kamiyama, MD, Kazuaki Nakanishi, MD, Hideki Yokoo, MD, Hirofumi Kamachi, MD, Michiaki Matsushita, MD, Satoru Todo, MD
Pulmonary for metastases from hepatocellular carcinoma: Factors influencing prognosis Takahito Nakagawa, MD, Toshiya Kamiyama, MD, Kazuaki Nakanishi, MD, Hideki Yokoo, MD, Hirofumi Kamachi, MD, Michiaki
More informationResearch Article The Impact of Changed Strategies for Patients with Cholangiocarcinoma in This Millenium
HPB Surgery Volume 2015, Article ID 736049, 6 pages http://dx.doi.org/10.1155/2015/736049 Research Article The Impact of Changed Strategies for Patients with Cholangiocarcinoma in This Millenium Per Lindnér,
More informationReconsidering Liver Transplantation for HCC in a Era of Organ shortage
Reconsidering Liver Transplantation for HCC in a Era of Organ shortage Professor Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital
More informationThymic neoplasms are the most common tumors of
Thymic Carcinoma: A Multivariate Analysis of Factors Predictive of Survival in 290 Patients Benny Weksler, MD, Rajeev Dhupar, MD, MBA, Vishal Parikh, BS, Katie S. Nason, MD, MPH, Arjun Pennathur, MD, and
More informationResearch Article Refusal of Cancer-Directed Surgery Strongly Impairs Survival of Patient with Localized Hepatocellular Carcinoma
International Surgical Oncology Volume 2010, Article ID 381795, 8 pages doi:10.1155/2010/381795 Research Article Refusal of Cancer-Directed Surgery Strongly Impairs Survival of Patient with Localized Hepatocellular
More informationCCSS Concept Proposal Working Group: Biostatistics and Epidemiology
Draft date: June 26, 2010 CCSS Concept Proposal Working Group: Biostatistics and Epidemiology Title: Conditional Survival in Pediatric Malignancies: A Comparison of CCSS and SEER Data Proposed Investigators:
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More informationExpression of mir-1294 is downregulated and predicts a poor prognosis in gastric cancer
European Review for Medical and Pharmacological Sciences 2018; 22: 5525-5530 Expression of mir-1294 is downregulated and predicts a poor prognosis in gastric cancer Y.-X. SHI, B.-L. YE, B.-R. HU, X.-J.
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationLiver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995
Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Steven H. Belle, Kimberly C. Beringer, and Katherine M. Detre T he Scientific Liver Transplant Registry (LTR) was established
More informationHistologic Characteristics Enhance Predictive Value of American Joint Committee on Cancer Staging in Resectable Pancreas Cancer
Original Article Histologic Characteristics Enhance Predictive Value of American Joint Committee on Cancer Staging in Resectable Pancreas Cancer James Helm, MD, PhD 1,2,3,4,5 ; Barbara A. Centeno, MD 3,6,7
More informationSystemic therapy for unresectable, mixed hepatocellularcholangiocarcinoma:
Original Article Systemic for unresectable, mixed hepatocellular: of a rare malignancy Jane E. Rogers 1, Ryan M. Bolonesi 2, Asif Rashid 3, Khaled M. Elsayes 4, Mohamed G. Elbanan 4, Lindsey Law 5, Ahmed
More informationDoes Buccal Cancer Have Worse Prognosis Than Other Oral Cavity Cancers?
The Laryngoscope VC 2014 The American Laryngological, Rhinological and Otological Society, Inc. Does Buccal Cancer Have Worse Prognosis Than Other Oral Cavity Cancers? P. Ryan Camilon, BA; William A. Stokes,
More informationNegative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma
Li et al. World Journal of Surgical Oncology (2015) 13:294 DOI 10.1186/s12957-015-0713-4 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Negative impact of low body mass index on liver cirrhosis
More informationCholangiocarcinoma: Not an Indication for Hepatic Transplantation. Joon Lee UCHSC Surgery Intern
Cholangiocarcinoma: Not an Indication for Hepatic Transplantation Joon Lee UCHSC Surgery Intern Objectives 1. Very brief overview of cholangiocarcinoma 2. Review current standards of care for patients
More informationSalvage Liver Transplantation for Recurrent Hepatocellular Carcinoma after Liver Resection: Retrospective Study of the Milan and Hangzhou Criteria
Salvage Liver Transplantation for Recurrent Hepatocellular Carcinoma after Liver Resection: Retrospective Study of the Milan and Hangzhou Criteria Zhenhua Hu 1,2,3, Jie Zhou 1,2,3, Zhiwei Li 1,2,3, Jie
More informationPrognostic Value of Plasma D-dimer in Patients with Resectable Esophageal Squamous Cell Carcinoma in China
1663 Ivyspring International Publisher Research Paper Journal of Cancer 2016; 7(12): 1663-1667. doi: 10.7150/jca.15216 Prognostic Value of Plasma D-dimer in Patients with Resectable Esophageal Squamous
More informationOriginal Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome
Int J Clin Exp Pathol 2017;10(2):2030-2035 www.ijcep.com /ISSN:1936-2625/IJCEP0009456 Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical
More informationSurvival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion
Title Author(s) Survival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion Chan, SC; Fan, ST; Chok, KSH; Cheung, TT; Chan,
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More information